Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

484 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Urinary bother, Urinalysis, and Two-Year Efficacy Follow-Up Results of Phase I Trial of Intravesical Bacillus Calmette-Guérin Combined with Intravenous Pembrolizumab in Recurrent or Persistent High-Grade Non-Muscle-Invasive Bladder Cancer after Previous Bacillus Calmette-Guérin Treatment.
Montgomery J, Lybbert D, Sana S, El-Zawahry A, Peabody J, Pearce T, Adams N, Deebajah M, Dynda D, Babaian K, Crabtree J, Delfino K, McVary K, Robinson K, Rao K, Alanee S. Montgomery J, et al. Among authors: peabody j. Clin Genitourin Cancer. 2024 Feb 28;22(3):102059. doi: 10.1016/j.clgc.2024.02.010. Online ahead of print. Clin Genitourin Cancer. 2024. PMID: 38554570
Phase I trial of intravesical Bacillus Calmette-Guérin combined with intravenous pembrolizumab in recurrent or persistent high-grade non-muscle-invasive bladder cancer after previous Bacillus Calmette-Guérin treatment.
Alanee S, Sana S, El-Zawahry A, Peabody J, Pearce T, Adams N, Deebajah M, Crabtree J, Delfino K, McVary K, Robinson K, Rao K. Alanee S, et al. Among authors: peabody j. World J Urol. 2021 Oct;39(10):3807-3813. doi: 10.1007/s00345-021-03716-3. Epub 2021 May 8. World J Urol. 2021. PMID: 33966128 Clinical Trial.
Utilizing lesion diameter and prostate specific antigen density to decide on magnetic resonance imaging guided confirmatory biopsy of prostate imaging reporting and data system score three lesions in African American prostate cancer patients managed with active surveillance.
Alanee S, Deebajah M, Dabaja A, Peabody J, Menon M. Alanee S, et al. Among authors: peabody j. Int Urol Nephrol. 2022 Apr;54(4):799-803. doi: 10.1007/s11255-022-03136-1. Epub 2022 Feb 9. Int Urol Nephrol. 2022. PMID: 35138582
The effect of multiplicity of PI-RADS 3 lesions on cancer detection rate of confirmatory targeted biopsy in patients diagnosed with prostate cancer and managed with active surveillance.
Yaguchi G, Tang HJ, Deebajah M, Keeley J, Pantelic M, Williamson S, Gupta N, Peabody JO, Menon M, Dabaja A, Alanee S. Yaguchi G, et al. Among authors: peabody jo. Urol Oncol. 2020 Jun;38(6):599.e9-599.e13. doi: 10.1016/j.urolonc.2020.03.002. Epub 2020 Apr 4. Urol Oncol. 2020. PMID: 32265090
AUTHOR REPLY.
Alanee S, Peabody J, Menon M. Alanee S, et al. Among authors: peabody j. Urology. 2020 Dec;146:188. doi: 10.1016/j.urology.2020.07.071. Urology. 2020. PMID: 33272426 No abstract available.
AUTHOR REPLY.
Alanee S, Peabody J, Menon M. Alanee S, et al. Among authors: peabody j. Urology. 2021 Feb;148:317-318. doi: 10.1016/j.urology.2020.11.038. Epub 2020 Dec 3. Urology. 2021. PMID: 33279614 No abstract available.
A propensity score matched analysis of the effects of African American race on the characteristics of regions of interests detected by magnetic resonance imaging of the prostate.
Deebajah M, Keeley J, Park H, Pantelic M, Gupta N, Williamson SR, Peabody J, Menon M, Dabaja A, Alanee S. Deebajah M, et al. Among authors: peabody j. Urol Oncol. 2019 Aug;37(8):531.e1-531.e5. doi: 10.1016/j.urolonc.2019.03.017. Epub 2019 Apr 18. Urol Oncol. 2019. PMID: 31005421
484 results